Vimarsana
Biggest News Aggregation in the World

Page 22 - Jeff Mclaughlin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jeff Mclaughlin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jeff Mclaughlin Today - Breaking & Trending Today

Less Talk, More Action: New Report Sponsored by ViiV Healthcare Provides Roadmap to Achieve Health Equity by 2040 - Vimarsana News

Less Talk, More Action: New Report Sponsored by ViiV Healthcare Provides Roadmap to Achieve Health Equity by 2040

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices votes unanimously to recommend Shingrix for immunocompromised adults aged 19 and up - Vimarsana News

US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices votes unanimously to recommend Shingrix for immunocompromised adults aged 19 and up

/PRNewswire/ -- GlaxoSmithKline plc today announced that the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices...

US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices votes unanimously to recommend Shingrix for immunocompromised adults aged 19 and up - Vimarsana News

US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices votes unanimously to recommend Shingrix for immunocompromised adults aged 19 and up

/PRNewswire/ -- GlaxoSmithKline plc today announced that the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices...

ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs - Vimarsana News

ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

The Phase III TANGO study is the third trial to provide long-term evidence for Dovato, reinforcing its use as a viable switch option for people living with HIV For media and investors only ViiV

Developer proposes 1-million-square-foot warehouse in New Stanton - Vimarsana News

Developer proposes 1-million-square-foot warehouse in New Stanton

Joe Napsha | Tribune-Review   TribLIVE's Daily and Weekly email newsletters deliver the news you want and information you need, right to your inbox. A 1-million-square-foot warehouse proposed for the site near the UPS warehouse and terminal in New Stanton could bring as many as 600 jobs to the community, the development firm’s representative told New Stanton officials. “It is enormous,” Jay Gomolak, chairman of the New Stanton planning commission, said of the warehouse proposed by SunCap Property Group of Charlotte, N.C. The planning commission recently recommended approval of the lan...